We are a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to safely and effectively address the large unmet medical need for the treatment of chronic pain.
The chronic pain epidemic represents a significant public health problem, yet it remains a highly complex and often misunderstood medical condition. At Centrexion Therapeutics, we have a deep understanding of the underlying pathophysiology of chronic pain. We believe we can leverage our knowledge of pain biology to develop targeted treatments that are specific to both the type and source of pain.
At Centrexion Therapeutics, we believe that the most effective way to treat chronic pain is through therapies that specifically target the origin of the pain signal.
This approach differs from other treatments such as opioids, which bind to specific receptors located throughout the body including in the brain, spinal cord and other nervous tissue rather than the specific source of chronic pain in the peripheral nervous system, or NSAIDs and steroids, which target the inflammatory response, not pain signaling.
We’re redefining the study of new pain therapies by using a three-pronged approach:
Reveal the pain pathways where our therapies will have the maximum therapeutic effect
Turning observations into interventions by validating the safety and efficacy of our therapies in companion animals with the same naturally-occurring chronic pain conditions as humans
Innovative, more efficient early-stage clinical trial strategies to inform and de-risk development
By combining big data analytics with our existing translational medicine activities, such as our pre-clinical studies and innovative clinical trial approach that capitalizes on advances made in disease areas such as oncology, we have a more fully-informed basis for indication selection and clinical development of our pain treatments.